Aurobindo Pharma is currently trading at Rs. 1038.00, up by 16.85 points or 1.65% from its previous closing of Rs. 1021.15 on the BSE.

The scrip opened at Rs. 1030.55 and has touched a high and low of Rs. 1046.00 and Rs. 1023.55 respectively. So far 60403 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1058.95 on 23-Nov-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023.

Last one week high and low of the scrip stood at Rs. 1046.00 and Rs. 1009.75 respectively. The current market cap of the company is Rs. 60987.42 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 40.74% and 7.42% respectively.

Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampule, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), PULMICORT RESPULES (budesonide) Inhalation Suspension by Astrazeneca Pharmaceuticals LP. The product is expected to be launched in FY25. The approved product has an estimated market size of $226.4 million for the twelve months ending September 2023, according to IQVIA.

This is the 173rd ANDA approval (including 9 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oral and sterile specialty products. Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampule is indicated for maintenance treatment of asthma and as prophylactic therapy in children of age 12 months to 8 years.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.